Samir Saba

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Samir Saba sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 1 currently recruiting 3 completed upper quartile by trial count

Samir Saba: 4 sponsored US clinical trials, 1 recruiting.

Samir Saba sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Acute Myocardial Infarction, with 1 trials.

Upper-quartile sponsor footprint

Samir Saba sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Samir Saba pipeline

1 recruiting of 4 indexed (25% open); 3 completed (75%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Acute Myocardial Infarction (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Samir Saba: open-pipeline peers nationwide

Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Samir Saba sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%20%40%60%80% Total trials Recruiting share Samir Saba4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action LabAB ScienceAbbott Point of CareAccutar BiotechnologyAdrienne G. Waks
Samir Saba sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Samir Saba sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

What to do with this Samir Saba page

4 registered trials is a research-attention snapshot, not an endorsement of Samir Saba or any single study.

  • 1 of Samir Saba's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Myocardial Infarction is the condition Samir Saba studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myocardial Infarction trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Samir Saba pipeline card: 4 registered trials from official public datasets.Report a data error.